A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features

NCT06564844 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

DRUG: Datopotamab Deruxtecan
DRUG: Rilvegostomig
DRUG: Carboplatin
DRUG: Cisplatin
DRUG: Etoposide
DRUG: Pemetrexed
DRUG: Vinorelbine
DRUG: UFT

Sponsor

AstraZeneca

Collaborators

[object Object]